ST. LOUIS PARK, Minn., Jan. 22, 2018 (GLOBE NEWSWIRE) — NeoChord, a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced a research collaboration with the Skirball Center for Innovation (SCI) at the Cardiovascular Research Foundation (CRF)to accelerate development of the company’s transcatheter program.
“We are delighted to partner with an organization aiming to transform the treatment of mitral valve repair using catheter-based techniques,” said Juan F. Granada, MD, President and Chief Executive Officer of CRF. “Transcatheter mitral valve repair provides a less invasive delivery option and expands the therapeutic options that patients have today. We look forward to collaborating with NeoChord on their transcatheter program to work toward improved quality of life for patients afflicted with mitral regurgitation.”
The Cardiovascular Research Foundation is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. For over 20 years, SCI has contributed to key advances in the treatment of cardiovascular disease and has played an essential role in bringing innovative new technologies, pharmacologic therapies, and treatment paradigms to patients.
“CRF has been instrumental in the rapid progress of innovation in interventional cardiology by establishing the safe use of new technologies and therapies for heart disease,” said David Chung, President and Chief Executive Officer of NeoChord. “This research collaboration provides NeoChord with access to world-renowned clinicians, researchers, and animal lab facilities as we move our transcatheter program through preclinical development.”
About NeoChord, Inc.
Founded in 2007 and based in St. Louis Park, Minnesota, NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair for DMR. NeoChord’s DS1000 system received CE market clearance in December 2012. NeoChord received IDE approval from the FDA for the US pivotal trial in May 2016. For more information, please visit the Company’s website at www.neochord.com.
The NeoChord DS1000 System is CE marked and approved for sale in Europe.
CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use.
NEOCHORD, DS1000, RECHORD, the stylized logos, and Transforming Mitral Valve Repair are registered trademarks or service marks of the NeoChord Corporation.
Contact:
Bruce Van Deman
NeoChord, Inc.
(952) 698-7812 or (949) 413-1301
bvandeman@neochord.com
